How to cite item

Is it useful to combine taxanes with targeted agents in mCRPC patients—have we hit the target in this phase II study with docetaxel and curcumin allowing going for a phase III study?

   
@article{TCR10123,
	author = {Elise Nassif and Constance Michel and Constance Thibault and Stéphane Oudard},
	title = {Is it useful to combine taxanes with targeted agents in mCRPC patients—have we hit the target in this phase II study with docetaxel and curcumin allowing going for a phase III study?},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 4},
	year = {2016},
	keywords = {},
	abstract = {Ten percent to 20% of men diagnosed with prostate cancer will eventually develop castration-resistant prostate cancer (CRPC). Standard treatment for symptomatic metastatic CRPC (mCRPC) has consisted of chemotherapy-based regimens in combination with steroids for the past two decades. Docetaxel with daily prednisone is the recommended first-line therapy for symptomatic mCRPC (1). Docetaxel is the first treatment to have shown an increase in median overall survival (OS) for mCRPC. With a gain of 2–3 months OS (2-4), three key phase II randomized or III studies demonstrated the clinical benefit of docetaxel over the previous standard treatment, the mitoxantrone, an anthracedione (1) (Table 1).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/10123}
}